No Data
No Data
Aopu Mai (688293.SH): currently the company has not laid off any employees.
Oupu Mai (688293.SH) recently stated during a reception with institutional investors that the company has not downsized. In the current unfavorable environment, all industries are facing the same difficulties. At the end of last year, the company launched its corporate annuity plan, hoping to enhance employee benefits, attract talent, and fulfill its social responsibilities.
The business team in the USA of Aopu Mai (688293.SH) has now been basically established.
Aopumai (688293.SH) stated during a recent meeting with institutional investors that their USA business team has mostly been established and team members have diverse backgrounds and rich experience. This year, the integration of different corporate cultures in the USA and China is more important for the USA team. Currently, they are also successfully negotiating with MINC in the USA, products have been tested in some American pharmaceutical companies, and some pharmaceutical companies will also visit the company for on-site audits and visits in the future. There will be more opportunities for cooperation in the future, but it will still take time from business contact to order fulfillment.
The controlling shareholder of Aupu Bio (688293.SH) proposed to distribute mid-term dividend for the year 2024.
Aupu Mai (688293.SH) announced that the company recently received a notice from the company's controlling shareholder, actual controller and directors ...
Aupu Mai (688293.SH) spent a total of 46.6059 million yuan to repurchase 0.9207% of its shares.
On July 1st, Gelunhui reported that UpMax (688293.SH) has repurchased a total of 1,056,703 shares of the company through the Shanghai Stock Exchange trading system by means of centralized competitive bidding trading until June 30, 2024, accounting for 0.9207% of the company's current total share capital of 114,772,460 shares, with a highest fill price of 58.00 yuan/share and a lowest fill price of 29.88 yuan/share. The total amount of the trade reached 46,605,916.14 yuan (excluding transaction fees such as trading commissions).
Declining Stock and Decent Financials: Is The Market Wrong About Shanghai OPM Biosciences Co., Ltd. (SHSE:688293)?
Shanghai OPM Biosciences (SHSE:688293) has had a rough three months with its share price down 18%. However, stock prices are usually driven by a company's financials over the long term, which in thi
Aupmai (688293.SH): Dacheng Chuanglian has cumulatively reduced its shareholding by 300,000 shares in the company, and the shareholding reduction plan has been completed.
On June 11th, Gelun Hui announced that on June 11, 2024, the company received a "Notice of Shareholding Reduction Results" from Dachenchuanglian during this shareholding reduction plan. Dachenchuanglian reduced the company's shares by 300,000 shares through centralized bidding trading, with a cumulative reduction ratio of 0.26% of the company's total share capital. The shareholding reduction plan has been completed.
No Data